Longeveron

HLHS Trials And Aging Demographics Will Expand Regenerative Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

17 Aug 25

Updated

17 Aug 25

AnalystHighTarget's Fair Value

US$10.45

92.3% undervalued

17 Aug

US$0.81

-65.7%

16.4%

Author's Valuation

US$10.5

92.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$10.5

92.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

67.67%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.79%

Calculation

US$3.58m

Earnings '28

57.69x

PE Ratio '28

US$206.76m

Market Cap '28

US$206.76m

Market Cap '28

16.25m

No. shares '28

US$12.72

Share Price '28

US$12.72 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$10.45

Fair Value '25